AllSci News
Henlius pushes tetra-specific T-cell engager into the clinic for SCLC, NEC
Shanghai Henlius Biotech has registered a first-in-human Phase I clinical trial evaluating pipeline candidate HLX3901 in adults with advanced small cell lung…
CSL and Eli Lilly enter USD 100m licensing agreement for clazakizumab
Australia-based CSL Ltd, announced an exclusive licensing agreement with Indianapolis, US-based Eli Lilly and Co., for the development and commercialization of clazakizumab.…
Nektar Therapeutics partners with UCSF to explore TNFR2 agonism against multiple sclerosis
Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company headquartered in San Francisco, announced an academic research collaboration with the University of California,…
J&J wins FDA nod for subcutaneous Rybrevant in NSCLC
The FDA approved a simplified once-monthly subcutaneous dosing schedule for Johnson & Johnson's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) in combination with Lazcluze (lazertinib) for first-line EGFR-mutated advanced NSCLC.
BeOne Medicines launches ADAM9-targeted ADC into first-in-human study
BeOne Medicines, the global oncology company formerly known as BeiGene, has registered a clinical trial for BG-C0979, the first ADAM9-targeted antibody-drug conjugate…
Compass Pathways plots approval course for psilocybin drug after successful pivotal study
UK-based Compass Pathways announced positive topline results from its second pivotal Phase III clinical trial evaluating COMP360, a proprietary crystalline formulation of…
GSK posts real-world data for Arexvy’s long-term outcomes impact
GSK announced positive real-world evidence from a large-scale observational study evaluating Arexvy (respiratory syncytial virus vaccine, adjuvanted) in adults aged 60 years…
GSK turns to JAX-NYSCF for 5-year collaboration on neurodegenerative diseases
The Jackson Laboratory–New York Stem Cell Foundation Collaborative (JAX-NYSCF) and GSK plc (LSE: GSK) have entered a five-year strategic research collaboration aimed…
Wegovy picks up EC approval for higher dosage
The European Commission (EC) has granted marketing authorization to Novo Nordisk for a new, higher dosage of Wegovy (semaglutide) for the treatment…
Ocular’s Axpaxli becomes first novel agent to beat anti-VEGF standard in wet AMD trial
Massachusetts-based Ocular Therapeutix announced positive topline results from the SOL-1 Phase III superiority trial of Axpaxli (OTX-TKI), an investigational bioresorbable intravitreal hydrogel…
Gilead in-licenses a second synthetic lethality candidate, from China’s Genhouse
Gilead Sciences, Inc., headquartered in Foster City, US, signed an exclusive global license agreement with Genhouse Bio Co., Ltd., based in Suzhou,…
Novartis set to expand Vanrafia to IgA nephropathy after strong Phase III
Novartis announced positive results from the Phase III APPLAUSE-IgAN clinical trial evaluating Vanrafia (iptacopan) in patients with IgA nephropathy (IgAN). Vanrafia is…
HanchorBio’s SIRPα fusion protein takes FDA orphan status in gastric cancer
HanchorBio, Inc. (TPEx: 7827), a clinical-stage biotechnology company headquartered in Taipei, Shanghai, and San Francisco, announced that the US FDA has granted…
Coherus Oncology moving towards public offering to support Loqtorzi commercialization
Redwood City, California-based Coherus Oncology, Inc. (Nasdaq: CHRS) announced a proposed underwritten public offering of its common stock on February 12, 2026.…
PTC calls time on FDA filing for Duchenne’s
PTC Therapeutics, headquartered in Warren, New Jersey, issued notice that its New Drug Application (NDA) with the US FDA for Translarna (ataluren)…
The AllSci Brief
Systematic R&D and deal news. Daily.